Scarica l'app Stockscreener
2.055
0.24%
-0.005
Precedente Chiudi:
$2.06
Aprire:
$2.02
Volume 24 ore:
2.49M
Relative Volume:
0.23
Capitalizzazione di mercato:
$638.76M
Reddito:
$160.03M
Utile/perdita netta:
$-128.58M
Rapporto P/E:
-4.8149
EPS:
-0.4268
Flusso di cassa netto:
$-121.21M
1 W Prestazione:
+18.79%
1M Prestazione:
+45.74%
6M Prestazione:
+30.89%
1 anno Prestazione:
+5.38%
Intervallo 1D:
$1.97
$2.09
Intervallo di 1 settimana:
$1.74
$2.21
Portata 52W:
$1.07
$3.435
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.055 | 638.76M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
102.95 | 178.15B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.96 | 122.75B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
308.54 | 118.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.52 | 65.98B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.33 | 51.49B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-09 | Ripresa | UBS | Neutral |
| 2026-03-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
PACB Stock Eyes AI Genomics Momentum With Verily, TychoBio Deals - StocksToTrade
PACB Stock Draws Traders As Verily, TychoBio AI Deals Land - Timothy Sykes
PACB Stock Pops As Verily, TychoBio Deals Fuel AI Genomics Story - Timothy Sykes
Pacific Biosciences of California, Inc. (PACB) stock price, news, quote and history - Yahoo Finance UK
Pacific Biosciences of California, Verily Health Agree on Multi-Year Biomedical AI Collaboration - www.marketscreener.com
Pacific Biosciences of California, Verily Health Agree on Multi-Year Biomedical AI Collaboration - Yahoo Finance
PacBio and Verily Health form genomic data collaboration - Investing.com
DNA sequencing and health data will be joined to help train AI - Stock Titan
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI - GlobeNewswire
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI - Yahoo Finance
Pacific Biosciences of California, Inc. (PACB) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors - Yahoo! Finance Canada
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors - Zacks Investment Research
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors - Yahoo Finance
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewswire
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics - TradingView
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics - Zacks Investment Research
PACB5949325 Bond Profile: Coupon and Redemption - TradingView
Weekly Recap: PACB Q2 results, narrowed guidance and TychoBio RNA AI - TradingView
Form 144 Pacific Biosciences of California For: 11 October By Investing.com - Investing.com South Africa
Pacific Biosciences CFO reports $2.05m stock sale - Investing.com
Form 4 Pacific Biosciences of California For: 10 October By Investing.com - Investing.com Nigeria
PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral - Yahoo Finance
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Yahoo Finance UK
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Zacks Investment Research
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Yahoo Finance
Pacific Biosciences of California Insider Sold Shares Worth $2,056,921, According to a Recent SEC Filing - www.marketscreener.com
PACB Slides As UBS Starts Coverage With Neutral Target - StocksToTrade
Harnessing the Kivvi tool to resolve the genetics of FSHD with HiFi sequencing - PacBio
Pacific Biosciences of California (PACB) Institutional Ownership 2026 - MarketBeat
Pacific Biosciences of California Insider Sold Shares Worth $2,056,921, According to a Recent SEC Filing - Yahoo Finance
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25 - Moomoo
Pacific Biosciences of California (NasdaqGS:PACB) Stock Forecast & Analyst Predictions - Simply Wall Street
500,000 option-exercise shares are part of an officer's planned sale at Pacific Biosciences (PACB). - Stock Titan
PACB Stock Slides As UBS Starts Coverage With Neutral Call - StocksToTrade
PacBio Slides as Recent Rally Cools and Investors Reassess Turnaround Risks - Quiver Quantitative
PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More Complicated - Yahoo Finance
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally - Yahoo Finance
PacBio (PACB) Partners with TychoBio to Advance RNA Therapy Deve - GuruFocus
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks - Benzinga
Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training - Yahoo Finance
Pacific Biosciences of California, Inc. (PACB) stock price, news, quote and history - Yahoo Finance Singapore
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics - marketscreener.com
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics - GlobeNewswire
Why PacBio (PACB) Stock Is Trading Up Today - Yahoo Finance
Why PacBio (PACB) Stock Is Trading Up Today - StockStory
Why PacBio (PACB) Stock Is Trading Up Today - The Globe and Mail
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
PACB5630687 Bond Profile: Coupon and Redemption - TradingView
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts - Yahoo Finance
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pacific Biosciences Of California Inc Azioni (PACB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jim Gibson | Officer |
Oct 06 '26 |
Proposed Sale |
2.87 |
661,815 |
1,899,409 |
0 |
| Gibson James R II | See Remarks |
Oct 06 '26 |
Sale |
3.11 |
661,815 |
2,056,921 |
1,083,848 |
| MARK VAN OENE | Officer |
Aug 17 '26 |
Proposed Sale |
1.13 |
26,911 |
30,512 |
0 |
| Van Oene Mark | See Remarks |
Aug 17 '26 |
Sale |
1.13 |
26,911 |
30,409 |
2,705,853 |
| Gibson James R II | See Remarks |
Apr 01 '26 |
Sale |
1.37 |
88,185 |
120,813 |
1,245,663 |
| JAMES GIBSON | Officer |
Apr 01 '26 |
Proposed Sale |
1.37 |
88,185 |
120,778 |
0 |
| HENRY CHRISTIAN O | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
12,497 |
18,920 |
3,581,813 |
| Van Oene Mark | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
6,504 |
9,847 |
2,243,634 |
| MARK D. VAN OENE | Officer |
Mar 03 '26 |
Proposed Sale |
1.51 |
6,504 |
9,849 |
0 |
| Farmer Michele | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
2,979 |
4,510 |
305,948 |
1.60%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):